Shanghai S.E.
03:30:00 14/05/2024 am IST
5-day change
1st Jan Change
8.34
CNY
+0.36%
-1.53%
-22.13%
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 27, 2021 at 06:33 pm IST
Shanghai Hile Bio-Technology Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 168.136 million compared to CNY 118.634 million a year ago. Operating income was CNY 28.709 million compared to operating loss of CNY 12.760 million a year ago. Net income was CNY 26.279 million compared to CNY 1.732 million a year ago. Basic earnings per share from continuing operations was CNY 0.040808 compared to CNY 0.002691 a year ago.
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
29/04
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
29/04
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
30/23/30
CI
Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index
18/23/18
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
28/23/28
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/23/27
CI
Shanghai Zhizhuo Enterprise Management Consulting Co., Ltd. agreed to acquire Shanghai Caiyin Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for CNY 2 million.
12/23/12
CI
Shandong Sinder Technology Co., Ltd agreed to acquire Shandong Hile Biological Products Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 110 million.
12/23/12
CI
Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit
11/23/11
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
11/23/11
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
28/22/28
CI
Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.
30/22/30
CI
Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.
30/22/30
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
29/22/29
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
28/22/28
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
29/21/29
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
27/21/27
CI
WuXi Vaccines Inc. announced that it expects to receive $136 million in funding from Shanghai Hile Bio-Technology Co., Ltd., WuXi Biologics Inc.
13/21/13
CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it has received CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership
29/21/29
CI
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A.
29/21/29
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
23/21/23
CI
WuXi Biologics Cayman : , Shanghai Hile to Restructure Vaccine JV
02/21/02
MT
Shanghai Hile Bio-Technology Co., Ltd. intends to acquire 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A. for CNY 56 million.
17/21/17
CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership
15/21/15
CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
27/20/27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.
More about the company
1st Jan change
Capi.
-22.13% 756M -14.44% 76.62B +14.56% 8.4B +25.88% 3.76B +18.24% 1.65B -8.82% 1.53B -22.51% 1.3B -3.32% 1.25B -10.11% 1.19B +4.27% 1.1B
Veterinary Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. 